Clarithromycin contraindications: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Contraindications== | |||
Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BIAXIN (CLARITHROMYCIN) TABLET, FILM COATED BIAXIN (CLARITHROMYCIN) TABLET, FILM COATED, EXTENDED RELEASE BIAXIN (CLARITHROMYCIN) GRANULE, FOR SUSPENSION [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa44552c-3cfe-4111-8aa5-4251aeed9be9 | publisher = | date = | accessdate = }}</ref> | Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. | ||
Concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see Drug Interactions). There have been post-marketing reports of drug interactions when clarithromycin and/or erythromycin are coadministered with [[cisapride]], [[pimozide]], [[astemizole]], or [[terfenadine]] resulting in cardiac arrhythmias ([[QT prolongation]], [[ventricular tachycardia]], [[ventricular fibrillation]], and [[torsades de pointes]]) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported. | |||
Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. | |||
Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes. | |||
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see WARNINGS). | |||
For information about contraindications of other drugs indicated in combination with BIAXIN, refer to the CONTRAINDICATIONS section of their package inserts.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BIAXIN (CLARITHROMYCIN) TABLET, FILM COATED BIAXIN (CLARITHROMYCIN) TABLET, FILM COATED, EXTENDED RELEASE BIAXIN (CLARITHROMYCIN) GRANULE, FOR SUSPENSION [ABBVIE INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa44552c-3cfe-4111-8aa5-4251aeed9be9 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 22:12, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Contraindications
Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin or any of its excipients, erythromycin, or any of the macrolide antibiotics.
Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin.
Concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, and ergotamine or dihydroergotamine (see Drug Interactions). There have been post-marketing reports of drug interactions when clarithromycin and/or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported.
Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment.
Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes.
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see WARNINGS).
For information about contraindications of other drugs indicated in combination with BIAXIN, refer to the CONTRAINDICATIONS section of their package inserts.[1]
References
Adapted from the FDA Package Insert.